Regeneron stock price target raised to $815 from $810 at Guggenheim

Regeneron Pharmaceuticals (REGN) reported robust second-quarter revenues of $3.7 billion, surpassing expectations by 13%, driven by strong Dupixent sales and resilient performance from the Eylea franchise, despite some Eylea 2mg erosion and Eylea HD PDUFA delays. This strong showing led multiple analysts, including Guggenheim and Bernstein, to raise their price targets and affirm positive ratings, reflecting confidence in REGN's financial health and growth prospects. Furthermore, the company signaled a strategic shift towards pursuing differentiated later-stage business development opportunities.

Analysis

Regeneron Pharmaceuticals (REGN) delivered a robust second quarter, with revenues of $3.7 billion surpassing consensus expectations by a significant 13%. This outperformance was primarily fueled by two key drivers: stronger-than-expected sales of Dupixent, which is benefiting from new indication launches, and the resilient performance of the Eylea franchise. Within Eylea, the newer high-dose formulation (Eylea HD) demonstrated strong uptake with a 16% quarter-over-quarter increase in unit demand, effectively helping to offset a 10% QoQ decline in the older 2mg version. The company guides for this 2mg erosion to continue at a similar rate into the second half of 2025. Adding to the positive momentum, Libtayo sales grew 25% year-over-year, establishing it as a billion-dollar annualized product. Financially, the company's fundamentals appear solid, evidenced by a 47.35% gross profit margin, a 15% return on equity, and a strong current ratio of 4.6. This financial strength supports a noteworthy strategic shift in business development, with management now expressing an interest in later-stage assets, a departure from its historical focus on early-stage opportunities. This positive operational picture is tempered by a regulatory delay for Eylea HD's PDUFA date due to site inspection issues at a third-party facility. Nonetheless, the strong quarterly results have prompted a wave of positive analyst revisions, with firms including Guggenheim, Bernstein, RBC, and Leerink all raising their price targets and reiterating outperform ratings.

Key Decisions for Investors

• The significant Q2 earnings beat, driven by robust Dupixent growth and a strong launch for Eylea HD, affirms the company's strong commercial execution and supports a bullish stance, particularly as the stock appears undervalued by some metrics.
• Investors should closely monitor the transition within the Eylea franchise, specifically whether the demand growth for Eylea HD can consistently outpace the guided 10% quarterly erosion of the legacy Eylea 2mg product.
• The primary near-term risk factor is the PDUFA delay for Eylea HD; resolution of the FDA site inspection issues at the Catalent facility represents a key catalyst to watch for.
• Regeneron's strategic pivot towards acquiring later-stage assets presents a new long-term value creation lever, and investors should assess any future M&A announcements for their potential to diversify revenue streams and accelerate growth.